LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Written by

in

Results presented at the 17th World Stroke Congress (WSC 2025)
LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial hemorrhage…

Continue Reading

More posts

Groq Powers HUMAIN One, a Real-Time AI Operating System for Enterprise

October 28, 2025
NVIDIA and Partners Build America’s AI Infrastructure and Create Blueprint to Power the Next Industrial Revolution

October 28, 2025
Picasso Portrait of Dora Maar Sells for $37M, Quadruple the Estimate

October 28, 2025
Precursor of dopamine increases willingness to wait for larger delayed rewards

October 28, 2025